Effects of
butoctamide (N-(2-ethylhexyl)-3-hydroxybutyramide, L-2) on the antitumor activity of
6-mercaptopurine (6-MP) against Ehrlich solid
tumors in mice were investigated. No change was observed in
tumor growth after either oral or intraperitoneal administration of
butoctamide (100 mg/kg/day X 7). This
drug increased the activity of a low dose of 6-MP (2.5 approximately 10 mg/kg/day. i.p., X 7), but did not change the activity of a high dose of 6-MP (40 approximately 80 mg/kg/day, i.p., X 7). The antitumor activity of
thioinosine (6-MP riboside) was similarly increased by administration of
butoctamide (100 mg/kg/day, i.p., X 7). On the other hand, concomitant administration of
butoctamide with
cyclophosphamide,
methotrexate,
mitomycin C or
adriamycin had no effect on the activity of these anticancer drugs. In
butoctamide (100 mg/kg/day, i.p., X 7)-treated mice, the antitumor activities of a single administration of 6-MP and
cyclophosphamide were not increased.
Butoctamide stimulated the
hypoxanthine-guanine phosphoribosyltransferase activity and inhibited the
xanthine oxidase activity of mouse liver, to a certain degree as compared to controls.
Butoctamide may promote conversion from 6 MP to
thioinosinic acid monophosphate to a biologically active state, rather than to
thiouric acid or
hypoxanthine which would be inactive.